Brilinta monotherapy reduced the risk of clinically relevant bleeding compared to aspirin + Brilinta in high-risk coronary patients according to phase IV independent TWILIGHT trial. AstraZeneca
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest